SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vineet Laboratories - Quaterly Results

12 Feb 2024 Evaluate
The Sales for the quarter ended December 2023 of Rs. 326.47 million declined by -51.10% from Rs. 667.65 millions.The Net Loss for the quarter ended December 2023 is Rs. -20.65 millions as compared to Net Profit of Rs. 13.92 millions of corresponding quarter ended December 2022Operating profit Margin for the quarter ended December 2023 slipped to -6.29% as compared to 19.53% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 326.47 667.65 -51.10 1135.43 1550.93 -26.79 2122.93 1911.72 11.05
Other Income 0.12 0.02 500.00 0.52 0.90 -42.22 1.23 2.85 -56.84
PBIDT -6.29 19.53 -132.21 38.38 19.43 97.53 77.82 134.46 -42.12
Interest 10.77 10.31 4.46 30.61 30.11 1.66 33.80 20.86 62.03
PBDT -17.06 9.22 -285.03 7.77 -10.68 -172.75 44.02 113.60 -61.25
Depreciation 6.26 5.08 23.23 18.47 17.55 5.24 23.73 20.16 17.71
PBT -23.32 4.14 -663.29 -10.70 -28.23 -62.10 20.29 93.44 -78.29
TAX -2.67 -9.78 -72.70 -1.73 -5.27 -67.17 7.77 27.07 -71.30
Deferred Tax 0.25 -7.38 -103.39 0.14 -2.87 -104.88 2.17 -4.76 -145.59
PAT -20.65 13.92 -248.35 -8.97 -22.96 -60.93 12.52 66.37 -81.14
Equity 92.19 92.19 0.00 92.19 92.19 0.00 92.19 92.19 0.00
PBIDTM(%) -1.93 2.93 -165.87 3.38 1.25 169.81 3.67 7.03 -47.88

Vineet Laboratories Share Price

39.50 -0.19 (-0.48%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×